OUR MISSION

To develop targeted cancer therapeutics that provide better outcomes for patients

We’re building an Australian company with an ambitious vision to revolutionise cancer treatment across the globe. With exceptional expertise in drug discovery and pre-clinical development, a pipeline of promising drug candidates, and a team comprised of experienced executives, Aucentra is poised for success.

Our next step is to expand our clinical activities to take our discoveries into Phase II clinical trials.

 

 OUR MANAGEMENT TEAM & ADVISORY BOARD

Professor Shudong Wang

Professor Shudong Wang

Founder & Managing Director

  • Head of Drug Discovery and Development, University of South Australia
  • Inventor of >90 patents
  • >150 publications
  • Former Head of Chemistry and Oncology Drug Discovery, Cyclacel, UK
  • Founder of two biotech companies
  • Consultant to multiple pharma companies
Joe Bayer

Joe Bayer

Chief Executive Officer

 

    • CEO and Board Director with over 30 years experience in a diverse range of healthcare, consumer products and pharmaceutical industries.
    • Broad range of senior management roles and director roles held in Australia, UK and Asia
    • Experience in listed companies both on the ASX and LSE (London Stock Exchange).
    • Strong skillset in strategic and operational management, M&A activity and corporate governance and compliance

 

 

 

Dr David Fuller

Dr David Fuller

Chief Medical Officer

 

  • Dr Fuller is an experienced pharmaceutical physician with over 30 years’ international experience in drug development & commercialisation with an emphasis on oncology
  • He has led successful major market drug approvals (US & EU), had multiple Regulatory Agency interactions (FDA & EMA) and has experience in designing and executing multiple Phase I, II and III studies (US, EU, Asia) both orphan and non-orphan indications
  • His R&D experience spans pre-clinical and clinical development, medical and regulatory affairs, pharmacovigilance and commercialisation in large and small cap environments
Dr Paul Wabnitz

Dr Paul Wabnitz

Clinical Research & Development Director

 

  • Medical Director and experienced Drug Development Consultant in Translational Medicine, Drug Design and Medicinal Chemistry.
  • Expertise in toxicology, clinical trial design, planning & execution of a first-in-human clinical study.
  • Extensive experience with complex novel drugs and targeted combination therapy.
Maria Maieli

Maria Maieli

Chief Financial Officer

 

  • Accomplished Executive working with Senior Management & Board to achieve global strategy
  • Extensive experience in commercially driven industries having worked 30 years in a combination of ASX listed, unlisted and private companies in the sectors of manufacturing, healthcare and services
  • Background knowledge in finance, corporate governance, risk and operations management
Charmaine Symons

Charmaine Symons

Director of Operations

 

  • Experience in executive operations and biotech management, with a focus within the health and biotech industry
  • Expertise in business processes, within the private and public sector, with broad skills in project planning and management
  • Specialised focus to strategically maximise organisational productivity and efficiency
Dr Jasmine Karanjia

Dr Jasmine Karanjia

Clinical Programs Officer

 

  • PhD in pharmacology with expertise in areas of Drug Discovery, Cancer Cell Biology, Pharmacokinetics and Mouse Xenograft Models
  • Prior industrial R&D experience in Drug Metabolism and Pharmacokinetics (DMPK) and Bio-analytical Method Development and Validation
Dr Theodosia Teo

Dr Theodosia Teo

Commercial and Clinical Planning Manager

  • PhD in cancer biology with > 8-years’ experience in pharmaceutical science
  • > 10-years laboratory experience especially experienced in meeting ISO standards
  • Strong scientific track records
  • Experienced in operating high-throughput genotyping system
Dr Mingfeng Yu

Dr Mingfeng Yu

Preclinical Program Manager

 

  • PhD in Organic Chemistry, with a focus on discovery of anti-tuberculosis metal complexes
  • 16-years experience in medicinal chemistry and drug discovery
  • Specialised in discovery of small-molecule enzyme inhibitors in oncology
  • Global industry experience
  • Extensive laboratory management experience
Professor Chris Pepper

Professor Chris Pepper

Scientific Advisory Board Member

 

  • R M Phillips Chair in Experimental Medicine at the Brighton and Sussex Medical School, UK
  • Extensive research career with a patient focus, with over 100 papers published in high impact factor journals
  • Focus on B-cell lymphocytic leukemia
  • Author of 9 global patents as co-founder of TeloNostiX
Dr John de Groot MD

Dr John de Groot MD

Scientific Advisory Board Member

 

  • Chief of the Neuro-Oncology Division at the University of California San Francisco
  • Specialised in the treatment of patients with brain tumours   
  • Served as Director of clinical research in neuro-oncology and interim Chair of the department of neuro-oncology at The University of Texas MD Anderson Cancer Center
Mr Jun Liu

Mr Jun Liu

Director

 

  • Board Member, Changzhou Qianhong Bio-pharma Co. Ltd 
  • Senior Biochemical Engineer
  • 30 years’ experience in drug R&D and manufacturing
  • Expert in industrial transformation of drugs from laboratory to production
Dr Jose Iglesias

Dr Jose Iglesias

Advisory Board Member

 

  • Independent oncology consultant, Director, APEX Oncology Consulting
  • International leader in clinical pharmaceutical development
  • >20 years’ experience as a Chief Medical Advisor or Director in the field of oncology
  • Led a range of international clinical trials
  • Worked for major international companies such as Eli Lily and AMGEN, as well as start-up and mid-tier biotech companies
Professor Ian Olver AM

Professor Ian Olver AM

Advisory Board Member

 

  • MBBS MD PhhD FRACP FAChPM MRACMA
  • Medical oncologist and bio-ethicist
  • Chaired 6 national cancer and ethics committees
  • Former CEO, Cancer Council Australia
  • Former Clinical Director, Royal Adelaide Hospital Cancer Centre
  • Established 2 clinical centers
  • >300 publications

OUR CONSUMER ADVISORY GROUP

John Clements

John Clements

Dr Marilyn Mackinder

Dr Marilyn Mackinder

Dahlia Matkovic

Dahlia Matkovic

Sarah Tinney

Sarah Tinney

Chris Tretheway

Chris Tretheway

Our Consumer Advisory Group exists to gain input from cancer survivors, as well as others whose lives have been touched by the disease, on our proposed research activities and findings, to ensure that issues important to consumers are identified, prioritised and shared.

Advisory Group members have the opportunity to contribute to our research and be the voice for cancer patients, an important interface between our scientists and the community, ensuring our projects remain focused on research that is impactful and can make a real difference for patients.

© 2020 AUCENTRA

Lab and Building image photography by Chris Oaten.